Tag: Bladder Cancer
Neoadjuvant enfortumab vedotin promising in MIBC ineligible for cisplatin
Better survival with neoadjuvant dose-dense MVAC regimen in MIBC
EAU TV: The best on bladder cancer and renal cell carcinoma
Best of EAU: Highlights on bladder cancer
ctDNA can guide adjuvant immunotherapy in muscle-invasive bladder cancer
Durvalumab ± tremelimumab by cisplatin eligibility in metastatic urothelial carcinoma
Circulating tumour cells could aid in the decision to give neoadjuvant chemotherapy
Poorer outcomes in bladder cancer predicted by race/ethnicity and gender
Enfortumab vedotin as a promising treatment option for bladder cancer: phase 3 results
Enfortumab vedotin as a promising treatment option for bladder cancer: phase 2 results
Signature DNA alterations in subtypes of bladder cancer
Better allocation of research dollars needed
Enfortumab vedotin and pembrolizumab in advanced bladder cancer: initial results
Largest safety study of its kind with atezolizumab in metastatic bladder cancer
Bladder cancer risk and early detection
Consensus treatment pathway for patients with limited pelvic lymph node involvement in otherwise localised bladder cancer
FGFR3 gene mutation: Favourable prognostic impact in bladder cancer
Bladder cancer in young patients
Spanish study directly links surgical volume with mortality in bladder cancer patients undergoing cystectomy
